Overview
You can access the company’s website by clicking here.
News
-
08 Jul 2019 2 min read
4D Pharma starts first trial in asthma
4D Pharma starts first trial in asthma – UK microbiome biotech 4D Pharma (DDDD) has started a clinical trial of a live biotherapeutic, MRx-4DP000, in asthma, the first time such a drug concept has been tested in this condition. The double-blind, placebo-controlled Phase I/II study will enrol 90 patients whose asthma is inadequately controlled on inhaled therapy. Patients will […]
-
07 Jun 2019 2 min read
Biotech firms brace for wave of Woodford fund liquidations
Biotech firms brace for wave of Woodford fund liquidations Arix Biosciences (ARIX), Reneuron (RENE), Mereo Biopharma (MPH) and 4D Pharma (DDDD) look set to be among the firms braced for the potential sale of all or parts of the shareholdings held by Woodford Invesmtent Management in the coming days, as the troubled manager appears to […]
-
10 Aug 2018 1 min read
Woodford finally closes chapter on failed Vernalis investment
Woodford finally closes chapter on failed Vernalis investment Neil Woodford’s eponymous Patient Capital Trust (WPCT) will have to look forward to receiving just £1.8m for the 30.6m shareholding – acquired in 2015 for £18.5m – in Vernalis, the UK biotech whose failed endeavour to break into the US cough/cold market led to it being put up […]
-
29 Jan 2018 5 min read
Henderson Opportunities returns to form
Henderson Opportunities returns to form – Henderson Opportunities says that its NAV total return for the year ended 31 October 2017 was 29.5%, while the All-Share returned 13.4%. This strong outperformance more than recovered the shortfall in the preceding year, in which the NAV total return was 0.4% whereas the benchmark total return was 12.2%. During […]
-
22 Jun 2016 3 min read
Henderson Opportunities suffers as large cap outperforms
Henderson Opportunities Trust has published interim figures covering the six months ended 30 April 2016. The company’s net asset value fell by 2.4% over the period, while the FTSE All Share Total Return ( the benchmark) remained flat. The share price fell by 8.8%, which was more than the NAV. At the end of April the […]
-
11 Dec 2015 3 min read
Edinburgh Worldwide benefits from strong healthcare performance
Edinburgh Worldwide Investment Trust, managed by Douglas Brodie (pictured), has announced its annual results for the year ended 31 October 2015. During the year the company’s NAV by 10.0% and its share price by 13.8% beating its comparative index, the S&P Global Small Cap Index, which increased by 3.5% in sterling terms. The Company says […]
-
23 Jun 2015 2 min read
Another great performance from Henderson Opportunities
Henderson Opportunities has published interim results for the six months ended 30 April 2015. Over that period the FTSE All-Share Index returned 9.2% but the fund’s net asset value returned almost double that, 17.6%. Unfortunately for shareholders though, the discount widened from 3% to 12.1% and so the return to shareholders was just 7.5% – […]
-
08 Jun 2015 1 min read
Biotechs boost Edinburgh Worldwide
Edinburgh Worldwide beat its benchmark by a decent margin over the six months ended 30 April 2015, returning 14.7% on net assets vs. a 10.4% return for the benchmark, the S&P Citigroup Global Small Cap Index, the return to shareholders was even better at 17.7% as the discount narrowed from 8.5% to 6.1%. There is […]
-
13 Feb 2015 3 min read
Henderson Opportunities outperforms in a difficult year
Over the year to the end of October 2014 Henderson Opportunities net asset value total return was 3.4%, ahead of its peer group (the AIC UK All Companies Sector) which returned 0.6% and ahead of the FTSE All-Share index which returned 1%. The share price did even better, returning 9.3%. The manager’s report has a […]